Abstract:This review comprehensively summarizes the advances in research for fibrosis. It emphasizes organ‐specific profibrotic cell types and molecular mechanisms of fibrosis, especially in the kidney, liver, lung, and heart. The authors highlight the advanced antifibrotic small molecule drugs and cellular therapies for fibrosis. These findings have critical implications for further research and clinical translation of medicine. As the final stage of disease‐related tissue injury and repair, fibrosis is characterized by excessive accumulation of the extracellular matrix. Unrestricted accumulation of stromal cells and matrix during fibrosis impairs the structure and function of organs, ultimately leading to organ failure. The major etiology of fibrosis is an injury caused by genetic heterogeneity, trauma, virus infection, alcohol, mechanical stimuli, and drug. Persistent abnormal activation of "quiescent" fibroblasts that interact with or do not interact with the immune system via complicated signaling cascades, in which parenchymal cells are also triggered, is identified as the main mechanism involved in the initiation and progression of fibrosis. Although the mechanisms of fibrosis are still largely unknown, multiple therapeutic strategies targeting identified molecular mechanisms have greatly attenuated fibrotic lesions in clinical trials. In this review, the organ‐specific molecular mechanisms of fibrosis is systematically summarized, including cardiac fibrosis, hepatic fibrosis, renal fibrosis, and pulmonary fibrosis. Some important signaling pathways associated with fibrosis are also introduced. Finally, the current antifibrotic strategies based on therapeutic targets and clinical trials are discussed. A comprehensive interpretation of the current mechanisms and therapeutic strategies targeting fibrosis will provide the fundamental theoretical basis not only for fibrosis but also for the development of antifibrotic therapies.

G Protein-Coupled Receptor Kinase 2 as Novel Therapeutic Target in Fibrotic Diseases

GRK2 promotes activation of lung fibroblast cells and contributes to pathogenesis of pulmonary fibrosis through increasing Smad3 expression

Targeting GRK2 and GRK5 for treating chronic degenerative diseases: Advances and future perspectives

The roles of G protein-coupled receptor kinase 2 in renal diseases

Pathophysiological roles of G-protein-coupled receptor kinases

Progranulin: A promising biomarker and therapeutic target for fibrotic diseases

Development of Inflammatory Immune Response-Related Drugs Based on G Protein-Coupled Receptor Kinase 2

Role and targeting of the AGC kinase family in pulmonary fibrosis (Review)

GRK5 Promoted Renal Fibrosis Via HDAC5/Smad3 Signaling Pathway.

G Protein-Coupled Receptor Kinases in the Inflammatory Response and Signaling

G protein-coupled receptor kinases: More than just kinases and not only for GPCRs

Transforming growth factor-β signaling: From tissue fibrosis to therapeutic opportunities

Research progress on drugs targeting the TGF-β signaling pathway in fibrotic diseases

Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies

Anti-fibrotic effects of pharmacologic FGF-2: a review of recent literature

GRK2 and GRK5 as therapeutic targets and their role in maladaptive and pathological cardiac hypertrophy

Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic Treatment of Non-Alcoholic Fatty Liver Disease

Double life: How GRK2 and β-arrestin signaling participate in diseases

Epigenetic Modifications in Fibrotic Diseases: Implications for Pathogenesis and Pharmacological Targets

G protein-coupled receptor kinase 2 as a novel therapeutic target for gland fibrosis of Sjögren's syndrome

Epigenetic modifications in fibrotic diseases: implications for pathogenesis and pharmacological targets.